Literature DB >> 33606986

Structural basis for IL-12 and IL-23 receptor sharing reveals a gateway for shaping actions on T versus NK cells.

Caleb R Glassman1, Yamuna Kalyani Mathiharan2, Kevin M Jude3, Leon Su2, Ouliana Panova2, Patrick J Lupardus2, Jamie B Spangler2, Lauren K Ely2, Christoph Thomas2, Georgios Skiniotis2, K Christopher Garcia4.   

Abstract

Interleukin-12 (IL-12) and IL-23 are heterodimeric cytokines that are produced by antigen-presenting cells to regulate the activation and differentiation of lymphocytes, and they share IL-12Rβ1 as a receptor signaling subunit. We present a crystal structure of the quaternary IL-23 (IL-23p19/p40)/IL-23R/IL-12Rβ1 complex, together with cryoelectron microscopy (cryo-EM) maps of the complete IL-12 (IL-12p35/p40)/IL-12Rβ2/IL-12Rβ1 and IL-23 receptor (IL-23R) complexes, which reveal "non-canonical" topologies where IL-12Rβ1 directly engages the common p40 subunit. We targeted the shared IL-12Rβ1/p40 interface to design a panel of IL-12 partial agonists that preserved interferon gamma (IFNγ) induction by CD8+ T cells but impaired cytokine production from natural killer (NK) cells in vitro. These cell-biased properties were recapitulated in vivo, where IL-12 partial agonists elicited anti-tumor immunity to MC-38 murine adenocarcinoma absent the NK-cell-mediated toxicity seen with wild-type IL-12. Thus, the structural mechanism of receptor sharing used by IL-12 family cytokines provides a protein interface blueprint for tuning this cytokine axis for therapeutics.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  IL-12; IL-23; immunology; receptor biology; signaling; structural biology

Mesh:

Substances:

Year:  2021        PMID: 33606986      PMCID: PMC7899134          DOI: 10.1016/j.cell.2021.01.018

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  90 in total

1.  WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27.

Authors:  Stefan Pflanz; Linda Hibbert; Jeanine Mattson; Rency Rosales; Elena Vaisberg; J Fernando Bazan; Joseph H Phillips; Terrill K McClanahan; Rene de Waal Malefyt; Robert A Kastelein
Journal:  J Immunol       Date:  2004-02-15       Impact factor: 5.422

2.  Substantial energetic improvement with minimal structural perturbation in a high affinity mutant antibody.

Authors:  K S Midelfort; H H Hernandez; S M Lippow; B Tidor; C L Drennan; K D Wittrup
Journal:  J Mol Biol       Date:  2004-10-22       Impact factor: 5.469

3.  Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab.

Authors:  Jacqueline M Benson; Clifford W Sachs; George Treacy; Honghui Zhou; Charles E Pendley; Carrie M Brodmerkel; Gopi Shankar; Mary A Mascelli
Journal:  Nat Biotechnol       Date:  2011-07       Impact factor: 54.908

4.  Cooperation of natural killer cell stimulatory factor/interleukin-12 with other stimuli in the induction of cytokines and cytotoxic cell-associated molecules in human T and NK cells.

Authors:  M Aste-Amezaga; A D'Andrea; M Kubin; G Trinchieri
Journal:  Cell Immunol       Date:  1994-07       Impact factor: 4.868

5.  Charged residues dominate a unique interlocking topography in the heterodimeric cytokine interleukin-12.

Authors:  C Yoon; S C Johnston; J Tang; M Stahl; J F Tobin; W S Somers
Journal:  EMBO J       Date:  2000-07-17       Impact factor: 11.598

6.  Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning.

Authors:  Hollie J Pegram; James C Lee; Erik G Hayman; Gavin H Imperato; Thomas F Tedder; Michel Sadelain; Renier J Brentjens
Journal:  Blood       Date:  2012-02-21       Impact factor: 22.113

7.  IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells.

Authors:  Stefan Pflanz; Jackie C Timans; Jeanne Cheung; Rency Rosales; Holger Kanzler; Jonathan Gilbert; Linda Hibbert; Tatyana Churakova; Marilyn Travis; Elena Vaisberg; Wendy M Blumenschein; Jeanine D Mattson; Janet L Wagner; Wayne To; Sandra Zurawski; Terrill K McClanahan; Daniel M Gorman; J Fernando Bazan; Rene de Waal Malefyt; Donna Rennick; Robert A Kastelein
Journal:  Immunity       Date:  2002-06       Impact factor: 31.745

8.  The lipid binding pleckstrin homology domain in UNC-104 kinesin is necessary for synaptic vesicle transport in Caenorhabditis elegans.

Authors:  Dieter R Klopfenstein; Ronald D Vale
Journal:  Mol Biol Cell       Date:  2004-05-21       Impact factor: 4.138

9.  IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways.

Authors:  Liang Zhou; Ivaylo I Ivanov; Rosanne Spolski; Roy Min; Kevin Shenderov; Takeshi Egawa; David E Levy; Warren J Leonard; Dan R Littman
Journal:  Nat Immunol       Date:  2007-06-20       Impact factor: 25.606

10.  Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts.

Authors:  L Zitvogel; H Tahara; P D Robbins; W J Storkus; M R Clarke; M A Nalesnik; M T Lotze
Journal:  J Immunol       Date:  1995-08-01       Impact factor: 5.422

View more
  19 in total

1.  TIGIT blockade enhances tumor response to radiotherapy via a CD103 + dendritic cell-dependent mechanism.

Authors:  Kaikai Zhao; Liyang Jiang; Youjiao Si; Shujie Zhou; Zhaoqin Huang; Xiangjiao Meng
Journal:  Cancer Immunol Immunother       Date:  2022-07-06       Impact factor: 6.968

2.  Differential IL-12 signaling induces human natural killer cell activating receptor-mediated ligand-specific expansion.

Authors:  Avishai Shemesh; Harry Pickering; Kole T Roybal; Lewis L Lanier
Journal:  J Exp Med       Date:  2022-06-27       Impact factor: 17.579

Review 3.  Emerging principles of cytokine pharmacology and therapeutics.

Authors:  Robert A Saxton; Caleb R Glassman; K Christopher Garcia
Journal:  Nat Rev Drug Discov       Date:  2022-09-21       Impact factor: 112.288

4.  Intratumorally anchored cytokine therapy.

Authors:  K Dane Wittrup; Howard L Kaufman; Michael M Schmidt; Darrell J Irvine
Journal:  Expert Opin Drug Deliv       Date:  2022-06-02       Impact factor: 8.129

5.  Masking the immunotoxicity of interleukin-12 by fusing it with a domain of its receptor via a tumour-protease-cleavable linker.

Authors:  Aslan Mansurov; Peyman Hosseinchi; Kevin Chang; Abigail L Lauterbach; Laura T Gray; Aaron T Alpar; Erica Budina; Anna J Slezak; Seounghun Kang; Shijie Cao; Ani Solanki; Suzana Gomes; John-Michael Williford; Melody A Swartz; Juan L Mendoza; Jun Ishihara; Jeffrey A Hubbell
Journal:  Nat Biomed Eng       Date:  2022-05-09       Impact factor: 29.234

6.  Green synthesized gold nanoparticles from Pseudobulbus Cremastrae seu Pleiones show efficacy against hepatic carcinoma potentially through immunoregulation.

Authors:  Junmo Zhu; Zijing Liu; Youwei Pu; Jie Xu; Sitong Zhang; Yixi Bao
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

Review 7.  The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy.

Authors:  Xiaohu Zheng; Yaqi Wu; Jiacheng Bi; Yingying Huang; Ying Cheng; Yangyang Li; Yuwei Wu; Guoshuai Cao; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2022-01-04       Impact factor: 11.530

8.  Structure of a Janus kinase cytokine receptor complex reveals the basis for dimeric activation.

Authors:  Caleb R Glassman; Naotaka Tsutsumi; Robert A Saxton; Patrick J Lupardus; Kevin M Jude; K Christopher Garcia
Journal:  Science       Date:  2022-03-10       Impact factor: 63.714

9.  Facile discovery of surrogate cytokine agonists.

Authors:  Michelle Yen; Junming Ren; Qingxiang Liu; Caleb R Glassman; Timothy P Sheahan; Lora K Picton; Fernando R Moreira; Arjun Rustagi; Kevin M Jude; Xiang Zhao; Catherine A Blish; Ralph S Baric; Leon L Su; K Christopher Garcia
Journal:  Cell       Date:  2022-03-23       Impact factor: 66.850

Review 10.  Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy.

Authors:  Mithunah Krishnamoorthy; Lara Gerhardt; Saman Maleki Vareki
Journal:  Cells       Date:  2021-05-11       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.